Compare Chubb Ltd (CB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Incyte Corporation — how do they compare? Chubb Ltd trades at $345.1 (market cap $133.90B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Chubb Ltd is far larger — about 5.5× Incyte Corporation's market cap, and Chubb Ltd pays a 1.18% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CB | INCY | |
|---|---|---|
Market Cap | $133.90B | $24.54B |
Sector | Financials | Health |
52-Week High | $363.50 | $129.93 |
52-Week Low | $268.20 | $81.61 |
Enterprise Value | $154.74B | $20.04B |
Dividend Yield | 1.18% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
